Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients [18]

Journal of Clinical Oncology

Volumn 23, Issue 31, 2005, Pages 8136-8139

  Willett, Christopher G ^a   Boucher, Yves ^b   Duda, Dan G ^b   Di Tomaso, Emmanuelle ^b   Munn, Lance L ^b   Tong, Ricky T ^b   Kozin, Sergey V ^b   Petit, Lucine ^b   Jain, Rakesh K ^b   Chung, Daniel C ^b   Sahani, Dushyant V ^b   Kalva, Sanjeeva P ^b   Cohen, Kenneth S ^c,d   Scadden, David T ^c,d   Fischman, Alan J ^b   Clark, Jeffrey W ^b   Ryan, David P ^b   Zhu, Andrew X ^b   Blaszkowsky, Lawrence S ^b   Shellito, Paul C ^b   Mino Kenudson, Mari ^b   Lauwers, Gregory Y ^b   more..

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD STEM CELL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; FLUOROURACIL; MONOCLONAL ANTIBODY;

ANTIANGIOGENIC ACTIVITY; ANTICOAGULANT THERAPY; ASTHENIA; BLEEDING; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; COLITIS; DIARRHEA; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; HYPERTENSION; INTESTINE PERFORATION; ISCHEMIA; LETTER; LEUKOPENIA; LUNG EMBOLISM; MONOTHERAPY; PAIN; PRIORITY JOURNAL; RECTUM CANCER; SMALL INTESTINE PERFORATION; TISSUE PRESSURE; TUMOR VASCULARIZATION; TUMOR VOLUME; WOUND HEALING IMPAIRMENT; AGED; DOSE RESPONSE; FEMALE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOVASCULARIZATION (PATHOLOGY); PHASE 1 CLINICAL TRIAL; PROGNOSIS; RADIATION DOSE; RECTUM TUMOR; SURVIVAL RATE; VASCULARIZATION;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RADIOTHERAPY DOSAGE; RECTAL NEOPLASMS; SURVIVAL RATE;

EID: 30944452436     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.5635     Document Type: Letter

References (17)

1. Ellis LM, Kirkpatrick P: Bevacizumab. Nat Rev Drug Discov 4:S8-S9, 2005
2. Willett CG, Boucher Y, di Tomaso E, et al: Direct evidence that the VEGF-specific antibody bevacizumab has anti-vascular effects in human rectal cancer. Nat Med 10:145-147, 2004
3. Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nature Med 7:987-989, 2001
4. Jain RK: Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307:58-62, 2005
5. Tong RT, Boucher Y, Kozin SV, et al: Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64:3731-3736, 2004
6. Winkler F, Kozin SV, Tong RT, et al: Kinetics of vascular normalization by VEGFR2 blockade governs tumor response to radiation. Cancer Cell 6:553-563, 2004
7. Wildiers H, Guetens G, De Boeck G, et al: Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 88:1979-1986, 2003
8. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
9. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65, 2003
10. Johnson DH, Fehrenbacher L, Novotny WF, et al: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184-2191, 2004
11. Okunieff P, Mester M, Wang J, et al: In vivo radioprotective effects of angiogenic growth factors on the small bowel of C3H mice. Radiat Res 150:204-211, 1998
12. Paris F, Fuks Z, Kang A, et al: Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293:293-297, 2001
13. Colon and Rectum, American Joint Commission on Cancer Cancer Staging Manual (ed 6th Edition). New York, Springer-Verlag, 2002, pp 121-130
14. Lee C, Heijn M, di Tomaso E, et al: Anti-vascular endothelial growth factor treatment augments tumor radiation Response under normoxic or hypoxic conditions. Cancer Res 60:5565-5570, 2000
15. Shaheen RM, Ahmad SA, Liu W, et al: Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer 85:584-589, 2001
16. Pidgeon GP, Barr MP, Harmey JH, et al: Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells. Br J Cancer 85:273-278, 2001
17. Maisonpierre PC, Suri C, Jones PF, et al: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277:55-60, 1997